Presidential order could accelerate approval of psychedelics
Mental Health Weekly April 27, 2026 DOI: 10.1002/mhw.34844 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Key points | The executive order directs federal agencies to expedite reviews of psychedelic drugs that have completed Phase 3 trials, potentially leading to faster rescheduling from Schedule I status. |
Abstract
A new executive order from the White House could jump‐start additional research and new approvals of psychedelic drugs for the treatment of serious mental illness (SMI). Among its provisions, the April 18 order directs federal agencies to expedite reviews of products that have successfully completed Phase 3 trials, so that they can be more rapidly rescheduled from their current Schedule I (no recognized medical use) status.